Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

--Eli Lilly and Company today announced its financial results for the third quarter of 2024.. "Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding ...

While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and especially sales growth -- would make many other pharmaceutical companies ...

Trulicity sales fell 22% to $1.30 billion. Guidance: Eli Lilly forecasts fiscal year 2024 sales of $45.4 billion—$46 billion, compared to prior guidance of $45.4 billion—$46.6 billion and ...

Among some of Lilly's other bigger sellers, sales of diabetes treatment Trulicity dropped 22.2% to $1.3 billion, as "competitive dynamics" offset higher prices, but that topped expectations of $1. ...

INN Insider News INN Insider News RSS Get our newsletter Order Prints May 14, 2025 INN Insider News ...

Eli Lilly’s diabetes drugs in short supply: FDA The FDA added Eli Lilly’s diabetes drugs Mounjaro and Trulicity to its list of medications in short supply Dec. 15.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, ...